GlaxoSmithKline Pharmaceuticals Limited 35.60bn 6.75bn 416.26bn 3.21k 62.04 24.89 55.99 11.69 39.60 39.60 209.31 98.74 1.01 2.59 14.85 11,088,370.00 19.24 11.01 36.09 17.88 61.70 55.77 18.96 12.25 1.38 554.80 0.0088 192.07 6.21 2.00 -2.91 5.78 -36.02 9.86 Glenmark Pharmaceuticals Ltd 122.48bn -10.18...
These include: solifenacin for over-active bladder (developed with our partner Yamanouchi Pharmaceuticals Ltd of Japan); Avandaryl, a fixed-dose combination treatment which will further extend the Avandia family of treatments for type 2 diabetes; and Epivir plus Ziagen, the first once-daily ...
(pharmaceuticals, vaccines, consumer healthcare). dividend drive has given a good summary of these results. the vaccines business was substantially grown with the acquisition of novartis' ( nvs ) vaccines business (apart from influenza vaccines) in 2015. this transaction also involved novartis ...
Site Apollo Avenue Pascal 2-4-6 Wavre 1300 Belgium GlaxoSmithKline Pharmaceuticals SA Site Apollo Avenue Pascal 2-4-6 Wavre 1300 Belgium ViiV Healthcare sprl Site Apollo Avenue Pascal 2-4-6 Wavre 1300 Belgium Bermuda Glaxo Finance Bermuda Limited Trinity Hall 43 Cedar Avenue Hamilton HM12 ...
GlaxoSmithKline Pharmaceuticals Ltd: Overview Share GlaxoSmithKline Pharmaceuticals Ltd (GSK India), a subsidiary of GlaxoSmithKline Plc manufactures and markets prescription medicines and vaccines. The prescription medicines include therapeutic areas such as, analgesic, anti-infective, cardiovascular, anti-inflamm...
GSK plc (GSK) is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS...
Key (v) (p) * † S A AL MAA NDA Vaccine Pharmaccine Compounds in Shionogi-GlaxoSmithKline Pharmaceuticals LLC joint venture In-license or other alliance relationship with third party Date of first submission Date of first regulatory approval (for MAA, this is the first EU approval letter) ...